Is Regeneron losing its R&D mystique? Analyst discounts big biotech’s runner-up development strategy in an increasingly commoditized world
Nobody disses Regeneron.
After building a megablockbuster out of Eylea and commanding massive respect for their new blockbuster Dupixent, partnered with Sanofi, bowing to company founders George Yancopoulos and Leonard Schleifer has become reflexive behavior in the industry. They did it their way, with billions to show for it.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.